Patents Expiring in December 2033
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||
| Amylyx | RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660-001 | Sep 29, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | |||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | |||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF DYSPAREUNIA | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
